Guardant Health CEO discusses AI on Fox Business
Following Q2 2026 earnings, Chairman and co-CEO Helmy Eltoukhy discussed AI's role in blood-based testing and precision medicine.
See the latest news and media coverage for Guardant Health. We track all announcements, press releases, and industry mentions in real time, all in one place.
Blood-based precision oncology company
guardanthealth.comLast updated
In short: Guardant Health expanded Shield™ test access globally and secured major U.S. insurance coverage, despite a significant legal patent loss.
Following Q2 2026 earnings, Chairman and co-CEO Helmy Eltoukhy discussed AI's role in blood-based testing and precision medicine.
Revenue grew 44% to $335M, driven by oncology and screening growth. Company now expects full-year revenue of $1.34-$1.36 billion.
The largest US commercial insurer covers Shield for CRC screening, expanding access to 100 million lives.
The ACS lists Shield™ as a blood-based colorectal screening option, noting it can expand access and help reach over 50 million unscreened Americans.
On July 30, 2026, Guardant Health Inc (GH) shares rose 5.8% to a current price of $152.35. Over the...
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance...
Guardant Health (GH) shares were up more than 6% in Friday trading following its Q2 results in the previous day. Late Thursday, the company reported...
Fred Alger Management, an investment management company, released its "Alger Small Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be...
Track Guardant Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Guardant Health and other trending companies.